|
Vomiting
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Visceral myopathy familial external ophthalmoplegia
|
0.300 |
Biomarker
|
disease |
CTD_human |
Mitochondrial neurogastrointestinal encephalopathy due to mutations in RRM2B.
|
19667227 |
2009 |
|
Ventricular Arrhythmia, CTCAE 5.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Ventricular Arrhythmia, CTCAE 3.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Ventricular Arrhythmia by ECG Finding
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Ventricular arrhythmia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Urothelial Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Infrequent alteration in the p53R2 gene in human transitional cell carcinoma of the urinary tract.
|
14707445 |
2004 |
|
Unilateral Hypotonia
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
A novel homozygous RRM2B missense mutation in association with severe mtDNA depletion.
|
19138848 |
2009 |
|
Ulcerative Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, it was concluded that the p53-p53R2-dependent DNA repair system is constitutively stimulated by butyric acid, which accumulates in UC inflammatory lesions.
|
16206288 |
2006 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In this article, we present a viable hypothesis about the roles of p53R2 in cancer progression and therapy resistance based on the roles of cytoplasmic p21 and mutant p53.
|
24486301 |
2014 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
RRM2B's relation to MPTP is not well known, and the role of RRM2B in cancer progression is controversial.
|
30662615 |
2018 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
This study provides the first time evidence that RRM2B is transcriptionally and functionally regulated independent of p53 pathway by FOXO3, and it establishes that FOXO3 and RRM2B could be used as predictive biomarkers for cancer progression.
|
24947616 |
2014 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Deregulation of the expression of p53R2, a p53-inducible homologue of the R2 subunit of ribonucleotide reductase, has been found in various human cancer tissues; however, the roles p53R2 plays in cancer progression and malignancy remain controversial.
|
21216934 |
2011 |
|
Tumor Progression
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
p53R2 overexpression in cervical cancer promotes AKT signaling and EMT, and is correlated with tumor progression, metastasis and poor prognosis.
|
28841361 |
2017 |
|
Tumor Progression
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
In this review article, we will discuss the situation in which cancer cells with hyperactive PI3K/Akt signaling can recruit p53R2 in favor of cancer progression and resistance to therapy.
|
25086499 |
2014 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
In the validation set, RRM2B was negatively related to tumor invasion (OR = 0.45, 95% CI = 0.19-0.99, P = 0.040) and lymph node involvement (OR = 0.48, 95% CI = 0.25-0.92, P = 0.026).
|
21415168 |
2011 |
|
Tumor Cell Invasion
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Positive p53R2 expression was significantly correlated with depth of invasion, lymph node metastasis, stage, and poor prognosis.
|
16778101 |
2006 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Thus, opposing regulation of hRRM2 and p53R2 in invasion potential might play a critical role in determining the invasion and metastasis phenotype in cancer cells.
|
17311703 |
2007 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
The expression of p53R2 was significantly correlated with the depth of invasion and the tumor stage. p53R2-targeting siRNA successfully knocked down p53R2 and significantly inhibited the growth of KHm5 and 6 cells.
|
22902076 |
2012 |
|
Tumor Cell Invasion
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
We further show that p53R2 is important for oncogenic growth, migration and invasion in cervical cancer cells.
|
28841361 |
2017 |
|
Steatohepatitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The explanted livers of the patients with heterozygous, truncating insertion mutations in RRM2B showed patchy micro- and macrovesicular steatosis, decreased mitochondrial DNA (mtDNA) content <30% of controls, and reduced respiratory chain complex activity; both patients had good post-transplant outcome.
|
27483465 |
2016 |
|
Status Epilepticus
|
0.300 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion.
|
17486094 |
2007 |
|
stage, cervical cancer
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
In this study, we investigated the expression and clinical significance of p53R2 in early-stage cervical cancer. p53R2 expression is significantly upregulated at both mRNA and protein levels in cervical cancer cells and tissues, compared with that in matched normal cervical cells and tissues, respectively. p53R2 overexpression is associated with increased risk of pelvic lymph node metastasis (PLNM, p = 0.001) and cancer relapse (p = 0.009).
|
28841361 |
2017 |
|
Squamous cell carcinoma of the head and neck
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In the study, real-time PCR was used to detect hRRM1 (rs12806698 C/A) and p53R2 (rs2290707 G/T) gene polymorphisms in Turkish HNSCC patients and healthy individuals.
|
24861915 |
2014 |
|
Squamous cell carcinoma of esophagus
|
0.040 |
Biomarker
|
disease |
BEFREE |
The DNA repair markers, p53R2 or ERCC1, angiogenic molecule (VEGF), and hedgehog signaling pathway factor Gli-1 also have potential to predict the response and prognosis of ESCC.
|
23605218 |
2014 |